Overview

Safety and Efficacy of Oral Belumosudil in Black or African American Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Status:
Not yet recruiting

Trial end date:
2025-06-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American male and female participants with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy aged 12 years and above. The duration of subject participation will be up to 4 weeks for screening, treatment until clinically significant progression of disease, and 4 weeks of follow-up i.e., up to approximately 12 months. 1 Cycle = 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Kadmon, a Sanofi Company

Treatments:

Belumosudil